EP
HALO icon

Essential Partners’s Halozyme HALO Stock Holding History

Essential Partners’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35K Sell
30
-16
-35% -$1.09K ﹤0.01% 1910
2026
Q1 		$2.97K Sell
46
-707
-94% -$49.8K ﹤0.01% 1828
2025
Q4 		$50.7K Sell
753
-162
-18% -$10.9K 0.02% 604
2025
Q3 		$67.1K Buy
915
+912
+30,400% +$60.6K 0.02% 528
2025
Q2 		$156 Buy
+3
New +$171 ﹤0.01% 1998

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Essential Partners's HALO Position: Q2 2026 in Review

Essential Partners reduced its Halozyme (HALO) stake by 35% in Q2 2026, selling an estimated $1.09K and leaving 30 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1910.

Essential Partners first reported a position in HALO in Q2 2025 and has held it in 5 quarters since. The position peaked at $67.1K in Q3 2025. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Essential Partners held 30 shares of Halozyme worth $2.35K as of Q2 2026.
  • Essential Partners sold 16 Halozyme shares in Q2 2026, an estimated $1.09K.
  • Halozyme made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1910 holding.
  • Essential Partners first reported a position in Halozyme in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Halozyme position peaked at $67.1K in Q3 2025.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.